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Abstract. ‘Plasma Healthcare’ is an emerging interdisciplinary research topic
of rapidly growing importance, exploring considerable opportunities at the
interface of plasma physics, chemistry and engineering with life sciences. Some
of the scientific discoveries reported so far have already demonstrated clear
benefits for healthcare in areas of medicine, food safety, environmental hygiene,
and cosmetics. Examples include ongoing studies of prion inactivation, chronic
wound treatment and plasma-mediated cancer therapy. Current research ranges
from basic physical processes, plasma chemical design, to the interaction of
plasmas with (i) eukaryotic (mammalian) cells; (ii) prokaryotic (bacteria) cells,
viruses, spores and fungi; (iii) DNA, lipids, proteins and cell membranes; and
(iv) living human, animal and plant tissues in the presence of biofluids. Of
diverse interests in this new field is the need for hospital disinfection, in particular
with respect to the alarming increase in bacterial resistance to antibiotics, the
concomitant needs in private practices, nursing homes etc, the applications in
personal hygiene—and the enticing possibility to ‘design’ plasmas as possible
pharmaceutical products, employing ionic as well as molecular agents for
medical treatment. The ‘delivery’ of the reactive plasma agents occurs at the
gaseous level, which means that there is no need for a carrier medium and access
to the treatment surface is optimal. This focus issue provides a close look at the
current state of the art in Plasma Medicine with a number of forefront research
articles as well as an introductory review.
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1. Introduction: plasmas in medicine
Gas plasmas represent the fourth state of matter after solid, liquid and gas, and are formed
when a gas is ionized. Spanning over a vast parametric range of electron density and electron
temperature, their behaviours change very significantly with profound scientific and application
implications in areas such as energy, space exploration, environment, semiconductor fabrication
and material modification, photonics and communication [1]. Directly relevant to this Focus
Issue is low-temperature plasmas generated either at reduced or atmospheric pressures. Their
electron temperature is typically a few electronvolts, sufficient to drive many reaction chemistry
for modifying DNA, proteins and cell membranes, whereas their gas temperature is close to
room temperature thus allowing their treatment of heat-sensitive living tissues. Biomedical
application of low-temperature plasmas has been regarded as one of the most significant
opportunities in plasma science [1].
Low-temperature plasmas are in general not in the local thermal equilibrium, and these
non-equilibrium plasmas can occur naturally (for example in the context of astrophysics [2])
or in laboratories [3, 4]. For most laboratory plasmas, cold atmospheric plasmas (CAP), also
known as atmospheric pressure glow discharges (APGDs), are of particular interest because
they can be used to interact directly with living tissues without the complication of a vacuum
chamber. Most current CAP plasmas are generated in helium or argon mixed with a small
amount of reactive gases such as oxygen [4]–[9]; however, they can also be generated in
molecular gases such as air [10, 11]. Operated at atmospheric pressure, their collision frequency
is in the terahertz range and their mean-free path is a few tens of nanometres. These characters
mean that ion energy is relatively low and reaction chemistry is rapid [3]. CAP offer direct
delivery of biologically relevant plasma species to sample surfaces. Some of the most relevant
issues in plasma medicine are
• Production of reactive atoms and molecules, in both the ground and excited states, that may
modify membrane chemistry and permeability of cells;
• Production of ionic species near and even on living tissues;
• Relationship of concentration of plasma species to efficacy of plasma-mediated biological
functions in order to establish dosage;
• Plasma design to effect a synergistic ‘cocktail’ of plasma agents for specific biomedical
purposes;
• Fast and purpose-specific delivery of plasma agents at the atomic/molecular level;
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3• Safety consideration to satisfy the WHO guidelines on toxicity, UV emission, temperature,
electric currents, etc.
Clearly, the use of plasmas in medicine opens up new vistas of treatment—a breakthrough that
could well become as important as that which was initiated by antibiotics. This is the vision.
On the practical side, the question is: what type of plasmas should be ‘designed’ for which
purpose? And further questions: are there already any immediate (or imminent) applications in
healthcare? What can plasmas ‘do’ that current medical treatment cannot? Where are plasmas
a more economical alternative to current standards? These and many more questions are the
subject of current research.
Of low-temperature plasmas, those generated at reduced pressures have been successful as
a route to medical sterilization [12]–[14]. A common perception is that their use of a vacuum
chamber may present an implementation barrier for treatment of living tissues as well as an
economical disadvantage when compared with CAP. As low-pressure low-temperature plasmas
are being advanced further, this perception may need to be revisited. Of CAP, their interaction
with a biological sample such as human tissue may be divided into three general categories:
direct plasmas (where the biological sample acts as an electrode and draws the most of the
electric current through the sample) [10, 15], indirect plasmas (where the electric current is
collected by an upstream electrode and the downstream biological sample is treated mostly by
neutral species and photons) [9], and hybrid plasmas (where the biological sample draws part
of the electric current and is treated by neutral species, charged particles and photons) [16, 17].
These three types of CAP–tissue interactions imply different compositions of the ‘cocktail’
of relevant plasma species as experienced by the tissue, and they also present different scaling
implications when surface topologies of living tissues are considered. Plasma–tissue interactions
are influenced strongly by surface conditions of tissues, and they must be made relatively
insusceptible to tissue surface conditions to ensure the reproducibility and reliability of plasma
treatment.
In this Focus Issue, some of the questions posed above are addressed directly, others will
be touched upon more or less as a matter of passing (see also the introductory review [18]).
It is clear from the publications that the broad field of ‘plasma healthcare’—which incorporates
medicine, food and hospital hygiene, cosmetics—is highly interdisciplinary. Expertise is needed
from medicine, biology, microbiology, plasma chemistry, plasma physics and engineering. To
build up teams or networks that bring all of this together for the future benefit of mankind is a
challenging task—one, which we hope will be furthered and advanced through this Focus Issue.
2. Preventive medicine using plasmas
This section is entitled ‘preventive medicine’, because this is the most applicable common
denominator for the topics summarized here. The themes cover hospital hygiene and
containment of diseases, plasma bactericidal effects, plasma modification of lipid layers
and plasma inactivation of proteins and prions. The main point of all these studies is to
investigate whether the plasma treatment has an effect such that—if eventually employed in
professionally—it would help to reduce the spread of diseases—i.e. prevent suffering and death
at an early stage.
The most efficient way to overcome diseases is to prevent them. If that is not possible (the
usual situation), the next most important step is containment—preventing the spread of diseases.
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4Accordingly, decontamination, sterilization and disinfection are major issues in healthcare, one
of our most important armaments in the fight against epidemics and the spread of contagious
diseases. In the case of hospital acquired infections, there are many excellent and efficient
sterilizers in use in hospitals, for example those employing different fluid active agents. The
obvious question is why we need another technology. Literature suggests that each disinfection
with fluids takes typically a few minutes to become really effective [19]–[21]. With typically
60 patient contacts per day, medical practitioners or nurses would have to disinfect their hands
for a total of 3 h each day—impossible in practice. In addition, fluids cannot readily enter into
tiny skin folds or penetrate under fingernails, where pathogens may reside, and they can have
side effects such as skin irritation or allergic reactions. Disinfection with plasmas, according to
current research results, is fast—typically a few seconds—and is benign to the skin. Plasmas, or
rather the reactive molecules produced in plasma–air–water vapour interactions, can penetrate
even into the smallest skin folds and destroy bacteria, something fluids and even UV radiation
cannot equal. So there is a health, a hygiene and an economic issue at stake.
Research is therefore intense into plasma sources capable of disinfecting large surfaces
and human tissues in a short time, with many innovative ideas proposed, as well as detailed
transport calculations and chemical models, which will influence such designs [22]–[26]. Many
questions remain. Can plasmas kill viruses? Can they destroy spores, fungi, biofilms, even
prions? Of course, apart from decontamination efficacy, there are other questions of great
interest. Are bacteria really killed by plasmas or merely inactivated? Being essentially a ‘surface
effect’ from the point of view of delivery of active agents, how deep plasma agents can reach
into tissue?
In this Focus Issue, there are a number of reports that address some of these questions.
Detailed three-dimensional atomic force microscopy measurements have shown the surface
disruption of bacteria that occurs after plasma irradiation. Such measurements yield information
about the mechanisms—and, most importantly, yield a direct answer to the question whether
plasma irradiation kills bacteria or merely inactivates them [27]. This is consistent with similar
atomic force microscopy results [28] and complements evidence of spore rupture observed
using scanning electron microscopy [29]. Plasma–fluid interaction, especially with biofilms, is
of great medical interest, e.g. in chronic wounds, cleansing of blood supplies, infectious diseases
that are propagated by fluid transmission (e.g. sneezing), etc. Efficient destruction of immersed
pathogens would be a major help to physicians. Research in this area is growing and recent
advances using different techniques are reported in [30, 31], and these new results follow nicely
earlier studies of biofilm inactivation using CAP [32, 33]. Also reported in this Focus issue
is spore-forming bacteria inactivation [34], consolidating and expanding the understanding of
earlier studies of CAP inactivation of spores [35]–[38]. This research will certainly gain in
momentum as different ‘tailored’ plasma chemical designs become available. Finally, prion
decontamination—a health issue that so far is lacking a convincing solution—is being tackled
with plasma irradiation [39, 40]. First results are encouraging, a breakthrough in this area would
be a spectacular success for plasma medicine.
3. Regenerative medicine using plasmas
The overall goal in the field of ‘plasma medicine’ points to ‘plasma pharmacology’, where
plasmas can be ‘designed’ for different desired purposes and applications especially in
regenerative medicine. A CAP can be ‘designed’ to change UV radiation, gas temperature,
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5electric field and especially plasma chemistry by adding, for example, different gases or
catalysts or/and by changing the electron energy distribution function. So far, only first steps
into the direction of ‘plasma pharmacology’ have been taken—this is a very ambitious and
difficult topic, since it not only depends on the way the plasma is generated and delivered, but
also on the organism and living tissues it is applied to.
In [41], cell biological studies are reported using an argon CAP plasma device, which
is specifically ‘designed’ for disinfection of chronic wounds. The efficiency of this plasma
is based on (a) the short-term reduction of the bacterial density in the wound area, which is
achieved in roughly equal parts by the plasma-generated UV radiation and reactive species;
and (b) the long-term post-irradiation inhibition of bacterial growth, which mainly results from
the reactive nitrogen and oxygen species produced by the plasma without causing any negative
effect on human cells. This interplay of requirements is fulfilled at certain plasma dosages or
concentrations of reactive nitrogen and oxygen species, where different effects on prokaryotic
and eukaryotic cells—deadly to the bacteria and supportive concerning cell regeneration in
human cells—were measured. Furthermore, this Focus Issue contains a number of reports that
address the extra- and intracellular chemistry, resulting from treatments with different plasma
devices and which are summarized in the following.
3.1. Extracellular biochemistry
In [31], the acidification of a thin water layer on a human lipid film (modelling the hydrolipid
film covering the epidermis on the human skin surface), which results from the treatment
with non-thermal atmospheric pressure dielectric barrier discharge (DBD), is analysed. The
measured shift in pH either results from adhesion of NOx species on the surface or from
the deposition of nitric acid by gaseous HNO3. These preliminary observations need further
investigations and might offer a first step into pH-targeted plasma therapies in dermatology
by ‘designing’ an optimum plasma source. In [42], it was shown that an APGD torch in
helium flow is capable of inducing temporary cell permeabilization. This permeabilization
is achieved by plasma-generated long-lived excited helium states, which reach the cell
membrane. By ‘designing’, i.e. inserting active agents into the plasma, the plasma-created
pores (with a diameter of ∼5–7 nm) open up the possibility to transfer active pharmaceutical
ingredients directly into the cell interior, where they can immediately develop their beneficial
effects.
3.2. Intracellular biochemistry
Depending on the plasma source, the ‘plasma design’ and the plasma dosage, plasmas can
be selective and therefore have an adverse (apoptotic) effect on melanoma skin cancer cells,
without damaging the healthy tissue [43]. A possible explanation for plasma-induced apoptosis
in cancer cells relies on the production of reactive oxygen species (ROS) by the plasma in fluid.
The ROS can penetrate the cells and therefore might induce high levels of DNA damage, which
as a result leads to the induction of apoptosis [44]–[46]. In [47], human melanoma cancer cell
studies were performed with a low-temperature radio-frequency atmospheric plasma device,
which operates with helium. The results obtained suggest that CAP inhibit the adhesion of
these cells by reducing the activity of those adhesion proteins, which are important in malignant
transformation and acquisition of metastatic phenotypes.
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need of high temperatures, depending on the applied dose [10, 48]. The cauterization effects
were achieved through selective plasma stimulation of complex biochemical processes, which
also take place during natural blood coagulation. According to newest research results [49],
the reactive atomic oxygen, which is generated by the plasma, activates erythrocyte—platelets
interactions—and therefore induces blood coagulation.
4. Conclusions and outlook
Plasma Healthcare topics are receiving increased attention, with biologists/medical researchers
and plasma physicists/chemists joining forces as well as their respective engineering,
technological, diagnostic and interpretative capabilities in an effort to detect and identify the
basic processes—with the aim to ‘design’ them for specific applications, eventually. At this
early stage—the field was started in earnest only a few years ago—naturally the research
uses the available ‘equipment’—the plasma sources that have been developed and which are
available in the respective research networks. Accordingly, the results and conclusions are still
specific—specific with respect to the plasma source and its operating parameters. But, as more
and more data are being assembled, a picture will emerge that points in the ‘right’ direction
for different desired applications—i.e. ‘designer plasmas’—and in the long run perhaps even
‘plasma pharmacy’.
Even based on the limited current level of research, there is every reason to assume that
plasmas can be designed (eventually) to achieve cell permeabilization for direct molecular
delivery of medical substances. Equally, by controlling cellular response, plasmas may
eventually be able to generate paracrine effects that propagate far into the cellular tissue.
Other plasmas may be designed to enhance cell growth, healing and regenerative effects. The
beginnings have already been seen [41].
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